AxoGen, Inc.
NASDAQ:AXGNMedical - Devices
+$0.25 today
- Market cap
- $3.40B
- Beta
- 1.12
- P/E (TTM)
- -73.4
- EPS (TTM)
- -$0.61
Volume 2.11M
Average 1.08M
AXGN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
AxoGen, Inc.NASDAQ: AXGN
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development grows, but more slowly than its trailing trend
Q3 FY2026 research & development of $8.95M rose 18.3% year over year, behind the +37.4% change in trailing-twelve-month research & development. Sequentially, it rose 4.2% from the prior quarter. Over 3 fiscal years it compounded at +8.7% a year.
Context
- Research & development amounted to 14.6% of revenue in FY2025, down 0.2 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +18.3% toward the trailing-twelve-month pace of +37.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 32.89M USD
- Year-over-year change
- +18.4%
- 4-year CAGR
- +8.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.89M | +18.4% |
| FY2024 | 2024-12-31 | 27.77M | +1.6% |
| FY2023 | 2023-12-31 | 27.34M | +6.7% |
| FY2022 | 2022-12-31 | 25.63M | +6.0% |
| FY2021 | 2021-12-31 | 24.18M | — |
Research & Development vs competitors
How AXGN compares with its peers on the latest reported figures
- AXGN's LTM Sep 2026 research & development of $37.43M is the 3rd highest of the 7 companies compared; the peer median is $12.73M.
- Its year-over-year change of +37.4% is the highest of 7, against a peer median of +0.1%.
- Research & development amounts to 14.0% of revenue for AXGN, versus a peer median of 9.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $73.35M | -11.4% | +3.1% | 3638.2% | |
| LTM Mar 2026 | $49.06M | +2.0% | +3.9% | 9.6% | |
| LTM Sep 2026 | $37.43M | +37.4% | +8.7% | 14.0% | |
| LTM Mar 2026 | $15.91M | +24.0% | +5.9% | 4.1% | |
| LTM Jun 2026 | $9.54M | +8.0% | +1.0% | 11.9% | |
| LTM Jun 2026 | $5.31M | -1.7% | +285.9% | — | |
| LTM Mar 2026 | $2.09M | -9.0% | +31.9% | 1.7% | |
| Peer median (excluding AXGN) | $12.73M | +0.1% | +4.9% | 9.6% | |
Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 127.36M | 138.58M | 159.01M | 187.34M | 225.21M |
| Cost of Revenue | 22.93M | 29.78M | 37.14M | 45.36M | 57.86M |
| Gross Profit | 104.43M | 108.81M | 121.87M | 141.98M | 167.35M |
| Gross Margin | 82.0% | 78.5% | 76.6% | 75.8% | 74.3% |
| Research & Development | 24.18M | 25.63M | 27.34M | 27.77M | 32.89M |
| Selling, General & Admin | 105.67M | 112.89M | 115.99M | 117.5M | 142.32M |
| Operating Expenses | 129.84M | 138.52M | 143.33M | 145.26M | 175.2M |
| Depreciation & Amortization | 4.74M | 4.85M | 5.55M | 7.84M | 8.19M |
| EBITDA | (20.89M) | (23.47M) | (13.33M) | 6.08M | 192K |
| EBITDA Margin | -16.4% | -16.9% | -8.4% | 3.2% | 0.1% |
| Operating Income | (25.42M) | (29.71M) | (21.46M) | (3.29M) | (7.85M) |
| Operating Margin | -20.0% | -21.4% | -13.5% | -1.8% | -3.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.36M | 624K | 2.84M | 8.21M | 7.7M |
| Other Income / Expenses | (1.57M) | 759K | (254K) | (6.68M) | (7.85M) |
| Income Before Tax | (26.99M) | (28.95M) | (21.72M) | (9.96M) | (15.7M) |
| Pre-Tax Margin | -21.2% | -20.9% | -13.7% | -5.3% | -7.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.99M) | (28.95M) | (21.72M) | (9.96M) | (15.7M) |
| Net Margin | -21.2% | -20.9% | -13.7% | -5.3% | -7.0% |
| EPS (Basic) | (0.65) | (0.69) | (0.51) | (0.23) | (0.34) |
| EPS (Diluted) | (0.65) | (0.69) | (0.51) | (0.23) | (0.34) |
| Weighted Avg Shares | 41.22M | 42.08M | 42.88M | 44.26M | 46.05M |
| Weighted Avg Shares (Diluted) | 41.22M | 42.08M | 42.88M | 44.26M | 46.05M |
AxoGen, Inc.
NASDAQ:AXGN
Intrinsic Alpha fair value
Locked
Current Price
$56.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.